View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 29, 2021updated 11 Jul 2022 9:48am

TFF obtains Health Canada approval for inhaled Covid-19 drug trial

Subject dosing in the trial will start next month with an aim to complete enrolment by the first quarter of next year.

TFF Pharmaceuticals has obtained Health Canada approval for a Phase I clinical trial of a dry powder formulation of antiviral therapy, niclosamide, to potentially treat Covid-19 and other diseases that are infectious.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

An oral anthelmintic drug, niclosamide demonstrated potent antiviral activity against the SARS-CoV-2 virus.

The Thin Film Freezing (TFF) technology of the company aided in producing a dry powder formulation of niclosamide. This formulation can be offered directly to the viral replication site in the lungs by inhalation.

The Phase I trial will have a single ascending dose (SAD) segment analysing single inhalation doses of 0.5mg, 2mg and 6mg niclosamide in three arms of healthy subjects.

In this segment, six subjects will be given the active drug while two participants will receive a placebo.

The SAD segment will be followed by a multiple ascending dose (MAD) portion in which every 12 hours, two groups of healthy subjects will be given 3mg and 6mg doses, respectively, for five days.

On obtaining favourable data from the Phase I trial, TFF Pharmaceuticals will commence a Phase II/III trial in Covid-19-infected patients.

The company expects to dose the first subject in the trial next month and intends to conclude participant enrolment by the early first quarter of next year.

TFF Pharmaceuticals CEO Glenn Mattes said: “Early on in the Covid-19 pandemic, niclosamide was identified as a highly promising option for treating severe Covid-19 because of its ability to inhibit cellular processes in the human cell that are required for SARS-CoV-2 replication, thereby inhibiting the production of new viral particles from infected cells.

“Our inhaled niclosamide powder, developed via TFF’s unique Thin Film Freezing technology platform, has been shown to reduce Covid-19 viral load in vivo and offers both direct delivery to the site of infection in the lung and more convenient outpatient administration compared to the IV administered approved antibody Covid-19 treatments.”

According to a deal signed in August last year, UNION Therapeutics holds an option to obtain a licence to the TFF technology for use with niclosamide.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology